Use of high-dose immunoglobulins in dermatology;Anwendung von hochdosierten intraven̈sen Immunglobulinen in der Dermatologie

JDDG - Journal of the German Society of Dermatology

Volumn 7, Issue 9, 2009, Pages 806-812

  Enk, Alexander ^a,b   Fierlbeck, Gerhard ^a   French, Lars ^a   Hertl, Michael ^a   Messer, Gerald ^a   Meurer, Michael ^a   Steinbrink, Kerstin ^a   Stingl, Georg ^a   Volc Platzer, Beatrice ^a   Zillikens, Detlef ^a  

^a Section Editor   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE;

ADJUVANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ATOPIC DERMATITIS; AUTOIMMUNE SKIN DISEASE; CHURG STRAUSS SYNDROME; COLLAGEN DISEASE; DERMATOLOGY; DERMATOMYOSITIS; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; EPIDERMOLYSIS BULLOSA ACQUISITA; EVIDENCE BASED MEDICINE; HUMAN; INCLUSION BODY MYOSITIS; LONG TERM CARE; LUPUS ERYTHEMATOSUS; LUPUS ERYTHEMATOSUS NEPHRITIS; MEDICAL DECISION MAKING; MICROSCOPIC POLYANGIITIS; MUCOCUTANEOUS LYMPH NODE SYNDROME; MULTIPLE CYCLE TREATMENT; MUSCLE STRENGTH; PARANEOPLASTIC PEMPHIGUS; PEMPHIGUS FOLIACEUS; PEMPHIGUS VULGARIS; POLYARTERITIS NODOSA; POLYMYOSITIS; PRIMARY HEALTH CARE; RECOMMENDED DRUG DOSE; REVIEW; SCLEROMYXEDEMA; SYSTEMIC VASCULITIS; TOXIC EPIDERMAL NECROLYSIS; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; URTICARIA; VASCULAR DISEASE; VESICULAR RASH; WEGENER GRANULOMATOSIS;

AUTOIMMUNE DISEASES; DECISION SUPPORT TECHNIQUES; DERMATOLOGY; GERMANY; HUMANS; IMMUNOGLOBULINS; PRACTICE GUIDELINES AS TOPIC; PRESCRIPTIONS; SKIN DISEASES;

EID: 69549116787     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2009.07118.x     Document Type: Review

References (25)

1. Amato AA, Barohn RJ, Jackson CE, Pappert EJ, Sahenk Z, Kissel JT. Inclusion body myositis: treatment with intravenous immunoglobulin. Neurology 1994 44 : 1516 1518.
2. Aries PM, Hellmich B, Gross WL. Intravenous immunglobulin therapy in vasculitis. Clin Rev All Immunol 2005 29 : 237 245.
3. Cherin P, Piette JC, Wechsler B, Bletry O, Ziza JM, Laraki R, et al. Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients. J Rheumatol 1994 21 : 1092 1097.
4. Choy EHS, Hoogendijk JE, Lecky B, Winer JB. Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Art. No.: CD003643.
5. Dalakas MC, Koffman B, Fujii M, Spector S, Sivakumar K, Cupler E. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 2001 56 : 323 327.
6. Dalakas MC. Update on the use of intravenous immune globulin in the treatment of patients with inflammatory muscle disease. J Clin Immunol 1995 15 : 70S 5S.
7. Enk A, Hertl M, Messer G, Meurer M, Rentz E, Zillikens D. The use of high dose intravenous immunoglobulins in dermatology. J Dtsch Dermatol Ges 2003 Mar 1 (3 183 190. German.
8. Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, Hunzicker T, Saurat JH, Tschopp J, French L. Inhibition of TEN by blockade of CD95 with human IVIg. Science 1998 Oct 282 : 490 493.
9. Mittmann N, Chan BC, Knowles S, Shear NH. IVIg for the treatment of toxic epidermal necrolysis. Skin therapy Lett 2007 Feb 12 (1 7 9.
10. Jolles S, Hughes J, Whittaker S. Der-matological uses of high-dose intravenous immunoglobulin. Arch Dermatol 1998 Jan 134 (1 80 6.
11. Jolles S, Hughes J. Use of IGIV in the treatment of atopic dermatitis, urticaria, scleromyxedema, pyoderma gangrenosum, psoriasis, and pretibial myxedema. Int Immunopharmacol 2006 Apr 6 (4 579 591. 2005 Dec 13. Review.
12. Karim A, Lawlor F, Black MM. Successful treatment of scleromyxoedema with high dose intravenous immunoglobulin. Clin Exp Dermatol 2004 May 29 (3 317 318.
13. Körber A, Franckson T, Grabbe S, Dissemond J 2007) Successful therapy of scleromyxoedema Arndt-Gottron with low-dose intravenous immunoglobulin. Journal of the European Academy of Dermatology and Venereology 2007 21 (4 553 554.
14. Kukova G, Bruch-Gerharz D, Gensch K, Ruzicka T, Reifenberger J. Skleromyxödem. Der Hautarzt 2006 57 (4 326.
15. Levy Y, George J, Fabbrizzi F, Rotman P, Paz Y, Shoenfeld Y. Marked improvement of Churg-Strauss vasculitis with intravenous gammaglobulins. Southern Medical Journal 1999 92 (4 412 414.
16. Levy Y, Langevitz P, Nacci F, Righi A, Conforti L, Generini S, Shoenfeld Y. Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: an open label study. Arthritis Rheum 2004 1005 1007.
17. Paul C, Lahfa M, Bachelez H, Chevret S, Dubertret L. A randomized controlled evaluator-blinded trial of intravenous immunoglobulin in adults with severe atopic dermatitis. Br J Dermatol 2002 Sep 147 (3 518 522.
18. Pereira FA, Mudgil AV, Rosmarin DM. Toxic epidermal necrolysis. J Am Acad Dermatol 2007 Feb 56 (2 181 200.
19. Prins C, Gelfand E W, French LE. Intravenous immunoglobulin: properties, mode of action and practical use in dermatology. Acta Derm Venereol 2007 87 : 206 218.
20. Richter C, Schnabel A, Csernok E, De Groot K, Reinhold-Keller E, Gross WL. Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunglobulin. Clin Exp Immunol 1995 101 : 2 7.
21. Sansome A, Dubowitz V. Intravenous immunoglobulin in juvenile dermatomyositis-four year review of nine cases. Arch Dis Child 1995 72 : 25 8.
22. Schanz S, Ulmer A, Fierlbeck G. Intravenous immunglobulin in livedo vasculitis: A new treatment option? A Am Acad Dermatol 2003 49 (3 555 556.
23. Shoenfeld Y, Katz U. IVIg therapy in autoimmunity and related disorders: our experience with a large cohort of patients. Autoimmunity 2005 38 (2 123 137.
24. Topf S, Simon M jr., Schell H, Lüftl M. Deutliche Besserung eines Skleromyxödem Arndt-Gottron durch hoch dosierte intravenöse Immunglobuline. Der Hautarzt 2006.
25. Toubi E, Kessel A, Shoenfeld Y. High dose intravenous immunoglobulins: an option in the treatment of systemic lupus erythematosus. Hum. Immunol 2005 66 : 395 402.